ArticleArthritis & rheumatology (Hoboken, N.J.)2022
A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 6 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Risk factors for idiopathic pulmonary fibrosis: an umbrella review of meta-analyses and mendelian randomization analyses.BMC pulmonary medicine · 2026Pooled it
- Detection of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.The European respiratory journal · 2026Guideline
- Meta-analysis identifies the major impact of patient classification on the ACPA association with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).Arthritis research & therapy · 2025Pooled it
- Screening for rheumatoid arthritis-associated interstitial lung disease-a Delphi-based consensus statement.Zeitschrift fur Rheumatologie · 2024Pooled it
- Pooled it
- Review
- Lung disease in rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Extra-articular rheumatoid arthritis: example of RA-associated interstitial lung disease.EULAR rheumatology open · 2026Review
- Protective Effects of Apolipoprotein A and High-Density Lipoprotein Cholesterol Against Interstitial Lung Disease in Rheumatoid Arthritis: The Mediating Role of Systemic Inflammation.Rheumatology and therapy · 2026Article
- Peripheral blood transcriptomic analysis of patients with rheumatoid arthritis associated interstitial lung disease reveals: distinct molecular signature with evidence of humoral and myeloid immunity.Arthritis research & therapy · 2026Article
- Elevated serum Slit3 independently predicts disease activity and interstitial lung disease in rheumatoid arthritis.Clinics (Sao Paulo, Brazil) · 2026Article
- Clinical Factors Associated with hrCT-Confirmed Interstitial Lung Disease in Rheumatoid Arthritis: A Retrospective Case-Control Study.Journal of clinical medicine · 2026Article
- Biomarkers on Fibrotic Lung Diseases Associated with Usual Interstitial Pneumonia.International journal of medical sciences · 2026Review
- Rheumatoid arthritis associated interstitial lung disease: diagnostic accuracy of lung ultrasound compared to chest high resolution computed tomography.Frontiers in medicine · 2026Article
- Development and external validation of a clinical-genetic risk identification model for rheumatoid arthritis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- The prevalence of interstitial lung disease and bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- MUC5B promoter variant and survival in rheumatoid arthritis-associated interstitial lung disease.Rheumatology (Oxford, England) · 2025Article
- Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA.The Lancet. Rheumatology · 2025Article
- Review of pulmonary manifestations of rheumatoid arthritis.Skeletal radiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 2 countries.
Funding
Abstract
objectivePatients at high risk of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) would benefit from being identified before the onset of respiratory symptoms; this can be done by screening patients with the use of chest high-resolution computed tomography (HRCT). Our objective was to develop and validate a risk score for patients who have subclinical RA-ILD.
methodsOur study included a discovery population and a replication population from 2 prospective RA cohorts (ESPOIR and TRANSLATE2, respectively) without pulmonary symptoms who had received chest HRCT scans. All patients were genotyped for MUC5B rs35705950. After multiple logistic regression, a risk score based on independent risk factors for subclinical RA-ILD was developed in the discovery population and tested for validation in the replication population.
resultsThe discovery population included 163 patients with RA, and the replication population included 89 patients with RA. The prevalence of subclinical RA-ILD was 19.0% and 16.9%, respectively. In the discovery population, independent risk factors for subclinical RA-ILD were presence of the MUC5B rs35705950 T allele (odds ratio [OR] 3.74 [95% confidence interval (95% CI) 1.37, 10.39]), male sex (OR 3.93 [95% CI 1.40, 11.39]), older age at RA onset (for each year, OR 1.10 [95% CI 1.04, 1.16]), and increased mean Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (for each unit, OR 2.03 [95% CI 1.24, 3.42]). We developed and validated a derived risk score with receiver operating characteristic areas under the curve of 0.82 (95% CI 0.70-0.94) for the discovery population and 0.78 (95% CI 0.65-0.92) for the replication population. Excluding MUC5B rs35705950 from the model provided a lower goodness of fit (likelihood ratio test, P = 0.01).
conclusionWe developed and validated a risk score that could help identify patients at high risk of subclinical RA-ILD. Our findings support an important contribution of MUC5B rs35705950 to subclinical RA-ILD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.